Kenji Chiba Selected Research

Sphingosine-1-Phosphate Receptors

10/2020	Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii.
1/2013	Fingolimod (FTY720) stimulates Ca(2+)/calcineurin signaling in fission yeast.
5/2012	Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis.
4/2012	Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
3/2011	Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
6/2009	[New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
4/2009	[A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
3/2008	[Therapeutic effect of S1P receptor modifying drugs for autoimmune diseases].
9/2007	FTY720 story. Its discovery and the following accelerated development of sphingosine 1-phosphate receptor agonists as immunomodulators based on reverse pharmacology.
12/2005	FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenji Chiba Research Topics

Disease

10	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 12/2005
10	Multiple Sclerosis 10/2020 - 12/2005
4	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 08/2015 - 12/2005
3	Inflammation (Inflammations) 10/2015 - 12/2005
3	Rheumatoid Arthritis 12/2013 - 12/2005
2	Neoplasms (Cancer) 03/2016 - 10/2003
2	Experimental Arthritis 12/2013 - 06/2009
2	Arthritis (Polyarthritis) 12/2013 - 10/2007
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022
1	Lymphadenopathy 01/2021
1	Immunoglobulin G4-Related Disease 01/2021
1	Reinfection 01/2021
1	Connective Tissue Diseases (Connective Tissue Disease) 01/2021
1	Eosinophilia 01/2021
1	Infections 01/2021
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2020
1	Vascular Diseases (Vascular Disease) 12/2019
1	Mental Disorders (Mental Disorder) 11/2014
1	Schizophrenia (Dementia Praecox) 11/2014
1	Major Depressive Disorder (Major Depressive Disorders) 11/2014
1	Encephalomyelitis (Myeloencephalitis) 06/2009
1	Lupus Nephritis 06/2009
1	Necrosis 01/2008
1	Liver Diseases (Liver Disease) 01/2008
1	Thymoma (Thymic Carcinoma) 12/2006
1	Demyelinating Diseases (Demyelinating Disease) 12/2005
1	Neoplasm Metastasis (Metastasis) 10/2003
1	Experimental Melanoma 10/2003
1	Melanoma (Melanoma, Malignant) 10/2003
1	Body Weight (Weight, Body) 10/2003

Drug/Important Bio-Agent (IBA)

13	Fingolimod Hydrochloride (FTY720)FDA Link 10/2020 - 12/2005
10	Sphingosine-1-Phosphate ReceptorsIBA 10/2020 - 12/2005
4	InterleukinsIBA 01/2022 - 10/2007
4	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 10/2020 - 09/2007
4	Therapeutic UsesIBA 08/2015 - 12/2005
3	Pharmaceutical PreparationsIBA 10/2020 - 10/2003
3	Immunosuppressive Agents (Immunosuppressants)IBA 03/2016 - 12/2005
3	CytokinesIBA 10/2015 - 12/2013
2	InterferonsIBA 01/2022 - 03/2011
2	Tacrolimus (Prograf)FDA LinkGeneric 01/2021 - 12/2005
2	Collagen Type II (Type II Collagen)IBA 12/2013 - 10/2007
2	Interleukin-17 (Interleukin 17)IBA 12/2013 - 10/2007
2	Messenger RNA (mRNA)IBA 12/2013 - 12/2006
1	RNA (Ribonucleic Acid)IBA 01/2022
1	Proton Pump InhibitorsIBA 01/2021
1	Chemokine CCL26IBA 01/2021
1	Proteins (Proteins, Gene)FDA Link 01/2021
1	GlucocorticoidsIBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	MagnesiumIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2020
1	Acute-Phase Proteins (Acute-Phase Protein)IBA 12/2019
1	Interleukin-10 (Interleukin 10)IBA 10/2015
1	Neurotransmitter Agents (Neurotransmitter)IBA 11/2014
1	Interleukin-15 (Interleukin 15)IBA 12/2013
1	GTP-Binding Proteins (G-Protein)IBA 01/2013
1	Interferon beta-1a FDA Link 04/2012
1	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2008
1	Transaminases (Aminotransferases)IBA 01/2008
1	Concanavalin AIBA 01/2008
1	Bile Acids and Salts (Bile Acids)IBA 01/2008
1	Dihydrotachysterol (AT 10)IBA 12/2006
1	AntigensIBA 12/2005
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 12/2005
1	Interferon-betaIBA 12/2005
1	Y 32885IBA 10/2003
1	matrigelIBA 10/2003
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2003
1	Antineoplastic Agents (Antineoplastics)IBA 10/2003
1	Protein Kinases (Protein Kinase)IBA 10/2003

Therapy/Procedure

2	Oral Administration 12/2013 - 10/2003
2	Therapeutics 04/2012 - 01/2008
1	Subcutaneous Injections 10/2003